Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$54.09 USD
-0.96 (-1.74%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $54.09 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HALO 54.09 -0.96(-1.74%)
Will HALO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HALO
Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales
Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View
Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected
Other News for HALO
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics
J&J wins another FDA label expansion for multiple myeloma therapy
Buy Rating for Halozyme Backed by DARZALEX FASPRO Approval and ENHANZE Patent Prospects
Maintaining a Hold: Assessing Halozyme’s ENHANZE Amidst Emerging Competitive Threats and Patent Dynamics